XML 114 R37.htm IDEA: XBRL DOCUMENT v3.26.1
Equity-settled share-based transactions
 12 Months Ended
Dec. 31, 2025
Disclosure of terms and conditions of share-based payment arrangement [abstract]  
Equity-settled share-based transactions Equity-settled share-based transactions
The Group’s equity incentive arrangements comprise the PHCL 2021 Share Incentive Plan (the “PHCL 2021 Plan”) and the Prenetics 2022 Share Incentive Plan (the “Prenetics 2022 Plan”).
No further awards are granted under the PHCL 2021 Plan. All RSUs with respect to PHCL ordinary shares that were outstanding under the PHCL 2021 Plan have been replaced by awards under the Prenetics 2022 Plan. The replacement of awards did not result in any incremental fair value over and above the original grant-date fair value of the awards cancelled under the PHCL 2021 Plan.
(a)Prenetics 2022 Plan
The number of RSUs and aggregate fair value of RSUs granted to certain employees, directors and third parties under Prenetics 2022 Plan were as follows,
Grant dateNumber of RSUs
Closing price per ordinary share less subscription price per ordinary share
Aggregate fair value of the RSUs
On May 18, 2022144,522 $7.64 $1,104 
On June 30, 20222,446,557 4.04 9,884 
On December 31, 2022946,330 2.00 1,893 
On February 1, 202366,666 1.49 99 
On June 23, 202316,486,108 0.90 14,875 
On June 30, 20232,403,529 0.79 1,903 
On December 31, 20237,928 3.39 27 
On June 3, 2024176,902 5.43 960 
On June 28, 202424,590 5.92 146 
On June 30, 202475,665 4.69 355 
On July 2, 202438,800 4.26 165 
On July 15, 202420,833 3.17 66 
On August 1, 202413,971 5.60 78 
On August 22, 202426,786 2.50 67 
On September 9, 202420,576 4.59 94 
On October 7, 202430,364 2.13 65 
On December 1, 20246,696 4.47 30 
On December 31, 202415,805 5.80 92 
On January 30, 202518,484 5.41 100 
On March 1, 202540,650 4.92 20 
On April 8, 20252,500 3.65 9 
On May 23, 202557,060 10.31 588 
On June 1, 2025538 9.30 5 
On June 16, 20259,352 7.01 66 
On June 30, 202560,975 8.52 520 
On July 1, 2025604 8.27 5 
On July 15, 2025272,332 8.25 2,247 
On August 1, 2025625 7.99 5 
On September 1, 2025656 7.60 5 
On September 15, 20259,601 9.78 94 
On October 1, 2025342 14.59 5 
On October 15, 20252,237 14.84 33 
On October 17, 202522,980 15.00 345 
On November 1, 202513,935 14.82 207 
On November 15, 202543,697 12.20 533 
On December 1, 2025339 14.75 5 
On December 31, 20255,643 15.75 89 
The RSUs granted were measured at the closing price per ordinary share less subscription price per ordinary share on grant date. The Company recognized employee share-based compensation benefits over the vesting period.
The RSUs outstanding at December 31, 2025 had an exercise price ranged from $0.001 to $2.96 per ordinary share (2024: from $0.001 to $3.00 per ordinary share), and a range of vesting period up to 3 years (2024: up to 3 years).
The number and weighted average exercise prices of the RSUs are as follows:
20252024
Weighted average exercise priceNumber of RSUsWeighted average exercise priceNumber of RSUs
Balance at January 1$0.06 9,906,708 $0.06 11,081,359 
Granted— 569,2460.91 444,292
Cancelled0.45 (428,265)0.64 (649,689)
Exercised— (8,096,232)0.24 (969,254)
Outstanding balance at December 31$— 1,951,457 $0.06 9,906,708
Exercisable balance at December 31$0.051 298,609 $0.065 3,920,731
During the year ended December 31, 2025, equity-settled share-based payment expenses in respect of the Prenetics 2022 Plan of $6,381 (2024: $5,416) was recognized in profit or loss, respectively. The remaining balance is recognized in profit or loss over the remaining vesting period.
(b)PHCL 2021 Plan
Details of the RSUs outstanding at December 31, 2025 and 2024 are as follows:
Number of instruments
20252024
RSUs granted to directors— 821,111
RSUs granted to employees— 2,126
RSUs granted to third parties11,71011,710
11,710834,947
Under the PHCL 2021 Plan, PHCL granted 3,933,063 RSUs to certain employees, directors and third parties on June 16, 2021 and 63,934 RSUs in December 2021 to certain directors, employees and third parties, respectively.
The fair value of services received in return for the RSUs granted was measured by reference to the fair value of share options granted in 2021 and 2022. The estimate of the fair value of the share options granted was measured based on Black-Scholes Model. The contractual life of RSUs was used as an input into this model.
 2021
Fair value of RSUs and key assumptions
Fair value at measurement date
$13.89 - $18.91
Share price
$13.89 - $18.91
Exercise price$0.01 
Expected volatility
41.03% - 44.26%
Expected option life1 year
Expected dividendsnil
Risk-free interest rate
1% - 1.13%
Likelihood of achieving a redemption event5 %
Likelihood of achieving a liquidity event5 %
The number and weighted average exercise prices of the RSUs are as follows:
20252024
Weighted
average
exercise price		Number of
RSUs 		Weighted
average
exercise price		Number of
RSUs
Balance at January 1$0.01 834,947$0.01 834,947
Exercised0.01 (823,237)n/a—
Outstanding balance at December 31$0.01 11,710$0.01 834,947
Exercisable balance at December 31$0.01 834,947$0.01 834,947
The RSUs outstanding at December 31, 2025 had a weighted average exercise price of $0.01 per ordinary share (2024: $0.01 per ordinary share). At December 31, 2025, these RSUs had zero remaining contractual life as all outstanding awards were fully vested (2024: 0.4 years).
The aggregate fair value of the RSUs granted to the selected employees on the dates of grants on June 30, 2021 and December 31, 2021 was $54,646 ($13.89 per share) and $1,209 ($18.91 per share) respectively. The Company recognized employee share-based compensation benefits according to the restriction conditions.
During the year ended December 31, 2024, equity-settled share-based payment expenses in respect of the PHCL 2021 Plan of $557 was recognized in profit or loss. At December 31, 2025, no balance of equity-settled share-based payment expenses was recognized, as all awards granted under the PHCL 2021 Plan were fully vested.
(c)Share options issued by ACT Genomics
The range of vesting period is from 2 to 3 years from the date of share options granted.
At December 31, 2025, no share options were outstanding following the disposal of ACT Genomics on October 1, 2025. At December 31, 2024, the share options outstanding had a weighted average exercise price of $0.01 per ordinary share and a weighted average remaining contractual life of 9.0 years and weighted average fair value at grant date of $0.33 dollar.
The fair value of share options granted by ACT Genomics was estimated on the date of grant using binomial lattice model. The assumptions that the Group used to determine the grant-date fair value of share options granted during the year end December 31, 2024 was as follows:
2024
Fair value at measurement date ($ cents)32.6
Share price ($ cents)32.6
Exercise price ($)0.01
Expected option life10 years
Risk-free interest rate3.85 %
Expected volatility
62.60% - 62.88%
Expected dividend yield0 %
Expected probability of a liquidation event0 %
During the year ended December 31, 2025, equity-settled share-based payment expenses in respect of the share options granted ACT Genomics of $1,226 (2024: $1,873) was recognized in profit or loss up to the date of disposal of ACT Genomics on October 1, 2025. Following the disposal, no further share-based payment expense will be recognized, and no remaining balance to be recognized in future periods.
(d)Ordinary shares of the Company issued to parties other than employees for service rendered
During the year ended December 31, 2024 and 2025, equity-settled share-based payment expenses of $4,132 and $— were recognized in profit or loss in relation to 721,106 ordinary shares and 6,148 ordinary shares of the Company issued to parties other than employees for service rendered, respectively. Such shares granted are measured at the market closing price of the shares of the Company granted at the date the counterparty renders the service.